Chronic Graft-versus-host-disease Clinical Trial
Official title:
A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation
In this study, a randomized, prospective, multicenter, open cohort study was conducted to investigate patients with acute leukemia (14~60-year-old) with different ATG doses (10 mg / kg and 12.5 mg / kg ) in fludarabine, busulfan, cyclophosphamide and antilymphocyte globulin (FBCA) pretreatment protocol of Haploidentical hematopoietic stem cell transplantation (haplo-HSCT). The purpose is to compare the incidences of chronic graft vs host disease (cGVHD) in haplo-HSCT recipients receiving different dose ATG and one year leukemia relapse after transplantation. The main objective was to investigate the optimal dose of ATG for decrease cGVHD and not increase one year relapse leukemia after haplo-HSCT. Its significance is to provide evidence-based medical evidence to reduce the occurrence of cGVHD and to improve the quality of life of patients with haplo-HSCT.
Status | Not yet recruiting |
Enrollment | 192 |
Est. completion date | September 30, 2021 |
Est. primary completion date | September 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 14 Years to 60 Years |
Eligibility |
Inclusion Criteria: 1. patients age between 14 yeas old and 60 years old 2. patients with acute myeloid leukemia and acute lymphoblastic leukemia who needed stem cell transplantation without available HLA-identical related or unrelated donors Exclusion Criteria: 1. Patients with severe infections 2. patients with major organ abnormal including renal, liver, lung or heart. 3. Patients with any conditions not suitable for the trial (investigators' decision) 4. patients age below 14 years old and more than 60 years old. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Zhujiang Hospital | First Affiliated Hospital, Sun Yat-Sen University, Nanfang Hospital of Southern Medical University, Second Affiliated Hospital, Sun Yat-Sen University |
Chang YJ, Wang Y, Mo XD, Zhang XH, Xu LP, Yan CH, Chen H, Chen YH, Chen Y, Han W, Wang FR, Wang JZ, Liu KY, Huang XJ. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial. Cancer. 2017 Mar 16. doi: 10.1002/cncr.30540. [Epub ahead of print] — View Citation
Lin X, Lu ZG, Song CY, Huang YX, Guo KY, Deng L, Tu SF, He YZ, Xu JH, Long H, Wu BY. Long-term outcome of HLA-haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion based on an FBCA conditioning regimen for hematologic malignancies. Bone Marrow Transplant. 2015 Aug;50(8):1092-7. doi: 10.1038/bmt.2015.108. Epub 2015 May 11. — View Citation
Long H, Lu ZG, Song CY, Huang YX, Xu JH, Xu JX, Deng L, Tu SF, He YZ, Lin X, Guo KY, Wu BY. Long-term outcomes of HLA-haploidentical stem cell transplantation based on an FBCA conditioning regimen compared with those of HLA-identical sibling stem cell transplantation for haematologic malignancies. Bone Marrow Transplant. 2016 Nov;51(11):1470-1475. doi: 10.1038/bmt.2016.170. Epub 2016 Jun 20. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | occurrence of chronic GVHD | chronic GVHD diagnosis based on National Institutes of Health (NIH) criterion | from the day of stem cell transplantation to one year after stem cell transplantation | |
Secondary | one year cumulative incidence of leukemia relapse | leukemia relapse base on morphology criterion | from the day of stem cell transplantation to one year after stem cell transplantation | |
Secondary | The cumulative incidence rate of acute GVHD | acute GVHD diagnosis based on NIH criterion | from the day of stem cell transplantation to one year after stem cell transplantation | |
Secondary | no relapse mortality one year | no relapse death | from the day of stem cell transplantation to one year after stem cell transplantation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04189432 -
Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease
|
Phase 2 | |
Terminated |
NCT03557749 -
Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
|
||
Completed |
NCT05121142 -
Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease
|
Phase 1 | |
Recruiting |
NCT04202835 -
ATG Plus PTCy vs ATG for CGVHD Prophylaxis
|
Phase 2 | |
Terminated |
NCT03640481 -
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
|
Phase 2 | |
Completed |
NCT01036958 -
Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease
|
||
Recruiting |
NCT04372524 -
Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
|
||
Active, not recruiting |
NCT03604692 -
A Phase 1/2 Study to Evaluate SNDX- 6352 in Participants With Active cGVHD
|
Phase 1/Phase 2 | |
Recruiting |
NCT05355675 -
The Association of Microbiota Composition With cGVHD After Allo-HSCT
|
||
Active, not recruiting |
NCT04710576 -
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
|
Phase 2 | |
Terminated |
NCT04200365 -
A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)
|
Phase 2 | |
Not yet recruiting |
NCT06263478 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
|
Phase 3 | |
Not yet recruiting |
NCT06388564 -
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
|
Phase 2 | |
Terminated |
NCT02123966 -
An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease
|
Phase 2 | |
Recruiting |
NCT05692713 -
Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)
|
||
Terminated |
NCT04446182 -
Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD
|
Phase 2 | |
Active, not recruiting |
NCT05305989 -
Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213
|
Phase 2 | |
Active, not recruiting |
NCT02340676 -
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD
|
Phase 2 | |
Completed |
NCT04540133 -
Dexamethasone Solution and Dexamethasone in Mucolox™
|
Phase 2 | |
Active, not recruiting |
NCT04716075 -
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
|
Phase 2 |